Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 24;10(11):e039067.
doi: 10.1136/bmjopen-2020-039067.

Randomised, double-blind, multicentre, phase Ⅰ/Ⅱ dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol

Wenliang Dong #  1   2 , Xiaoyan Nie #  2 , Jiaxue Wang  1   2 , Lin Xia  3 , Lin Cai  4 , Qian Wang  1 , Wei Wang  5 , Weixing Fu  5 , Qi Wang  1   2 , Tiantian Shen  3 , Huaying Fan  6 , Suping Niu  6 , Yimin Cui  7 , Qingshan Zheng  8 , Jianzhong Zhang  4 , Yi Fang  9
Affiliations

Randomised, double-blind, multicentre, phase Ⅰ/Ⅱ dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol

Wenliang Dong et al. BMJ Open. .

Abstract

Introduction: Psoriasis is a life-long, immune-mediated disease that greatly reduces the quality of life of patients. Plaque psoriasis is the most common form of psoriasis. Treatment options for plaque psoriasis with good tolerance and sufficient response remain profoundly limited. Based on mechanistic findings that suggest the key pathogenic role of interleukin (IL)-17 in plaque psoriasis, we hypothesise that GR1501, a new monoclonal antibody (IL-17A targeted), will be an efficacious treatment for plaque psoriasis. This phase I/II trial aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of GR1501.

Methods and analysis: A multicentre, randomised, double-blind, phase I/II dose escalation and expansion trial will be conducted at four hospitals in China. In total, 226 patients with plaque psoriasis will be enrolled in the study, with 46 cases in the dose-escalation stage and 180 cases randomised to GR1501 or the placebo in a 3:1 ratio in the expansion cohort. The primary outcomes are safety and tolerability; the secondary outcomes include pharmacokinetics, immunogenicity and efficacy.

Ethics and dissemination: The study is in accordance with the Declaration of Helsinki, and the ethics approvals of the protocol have been obtained from the ethics committees of all participating centres, including Peking University People's Hospital, Chinese PLA General Hospital, The First Affiliated Hospital, College of Medicine, Zhejiang University and the Second Xiangya Hospital of Central South University. The findings of the study will be presented in published journals or at scientific conferences or meetings.

Trial registration number: ChiCTR1800017956.

Keywords: clinical pharmacology; clinical trials; psoriasis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: WW and WF are employees of Genrix (Shanghai) Biopharmaceutical Co.

Figures

Figure 1
Figure 1
Schematic overview of the dose-escalation stage.
Figure 2
Figure 2
Schematic overview of the expansion cohort.
See this image and copyright information in PMC

References

    1. Boehncke W-H, Schön MP. Psoriasis. Lancet 2015;386:983–94. 10.1016/S0140-6736(14)61909-7 - DOI - PubMed
    1. Parisi R, Symmons DPM, Griffiths CEM, et al. . Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377–85. 10.1038/jid.2012.339 - DOI - PubMed
    1. Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, et al. . The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr 2016;107:577–90. 10.1016/j.ad.2016.04.018 - DOI - PubMed
    1. Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 2017;47:351–60. 10.1016/j.semarthrit.2017.05.010 - DOI - PubMed
    1. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015;27:127–33. 10.1097/BOR.0000000000000147 - DOI - PubMed

Publication types

Substances